| 1 |
Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study. Arterioscler Thromb Vasc Biol 2023;43:482-91. [PMID: 36727522 DOI: 10.1161/ATVBAHA.122.318661] [Reference Citation Analysis]
|
| 2 |
Indira Chandran V, Wernberg CW, Lauridsen MM, Skytthe MK, Bendixen SM, Larsen FT, Hansen CD, Grønkjær LL, Siersbæk MS, Caterino TD, Detlefsen S, Møller HJ, Grøntved L, Ravnskjaer K, Moestrup SK, Thiele MS, Krag A, Graversen JH. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology 2023;77:558-72. [PMID: 35712786 DOI: 10.1002/hep.32620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 3 |
Zhang S, Mak LY, Yuen MF, Seto WK. Screening strategy for non-alcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S103-22. [PMID: 36447420 DOI: 10.3350/cmh.2022.0336] [Reference Citation Analysis]
|
| 4 |
Nasiri-Ansari N, Kassi E. Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances. Metabol Open 2023;17:100229. [PMID: 36686606 DOI: 10.1016/j.metop.2023.100229] [Reference Citation Analysis]
|
| 5 |
Hou J, Liu Y, Deng Z, Sun J, Zhao M. Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: Study from the NHANES 2017- 2020. Front Endocrinol (Lausanne) 2022;13:1078652. [PMID: 36619581 DOI: 10.3389/fendo.2022.1078652] [Reference Citation Analysis]
|
| 6 |
Lee WL, Wang PH, Yang ST, Liu CH, Chang WH, Lee FK. To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases. J Chin Med Assoc 2022;85:1109-19. [PMID: 36279128 DOI: 10.1097/JCMA.0000000000000831] [Reference Citation Analysis]
|
| 7 |
Khairnar R, Islam MA, Fleishman J, Kumar S. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci 2022;312:121185. [PMID: 36375569 DOI: 10.1016/j.lfs.2022.121185] [Reference Citation Analysis]
|
| 8 |
Ahmed ES, Mohamed HE, Farrag MA. Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway. Int J Immunopathol Pharmacol 2022;36:3946320221137435. [PMID: 36319192 DOI: 10.1177/03946320221137435] [Reference Citation Analysis]
|
| 9 |
Vyletelová V, Nováková M, Pašková Ľ. Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals 2022;15:1278. [DOI: 10.3390/ph15101278] [Reference Citation Analysis]
|
| 10 |
Freer CL, George ES, Tan SY, Abbott G, Dunstan DW, Daly RM. Effect of progressive resistance training with weight loss compared with weight loss alone on the fatty liver index in older adults with type 2 diabetes: secondary analysis of a 12-month randomized controlled trial. BMJ Open Diabetes Res Care 2022;10:e002950. [PMID: 36220197 DOI: 10.1136/bmjdrc-2022-002950] [Reference Citation Analysis]
|
| 11 |
Assarrar I, Messaoudi N, Ongoth FEM, Abdellaoui W, Malki A, Rouf S, Abda N, Ismaili Z, Latrech H. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study. Rev Diabet Stud 2022;18:140-5. [PMID: 36309775 DOI: 10.1900/RDS.2022.18.140] [Reference Citation Analysis]
|
| 12 |
Roy B, Runa SA. SARS-CoV-2 infection and diabetes: Pathophysiological mechanism of multi-system organ failure. World J Virol 2022; 11(5): 252-274 [DOI: 10.5501/wjv.v11.i5.252] [Reference Citation Analysis]
|
| 13 |
Cazac G, Lăcătușu C, Mihai C, Grigorescu E, Onofriescu A, Mihai B. Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines 2022;10:2375. [DOI: 10.3390/biomedicines10102375] [Reference Citation Analysis]
|
| 14 |
Basu R, Noureddin M, Clark JM. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clin Proc 2022;97:1700-16. [PMID: 36058582 DOI: 10.1016/j.mayocp.2022.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Bonnet L, Alexandersson I, Baboota RK, Kroon T, Oscarsson J, Smith U, Boucher J. Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH. Front Endocrinol 2022;13:957616. [DOI: 10.3389/fendo.2022.957616] [Reference Citation Analysis]
|
| 16 |
Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e168-85. [PMID: 35418240 DOI: 10.1161/ATV.0000000000000153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 17 |
Rajapaksha IG, Gunarathne LS, Asadi K, Laybutt R, Andrikopoulous S, Alexander IE, Watt MJ, Angus PW, Herath CB. Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. Hepatol Commun 2022;6:1056-72. [PMID: 34951153 DOI: 10.1002/hep4.1884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Pimentel JL, Vander Wyst KB, Soltero EG, Peña A, Hu HH, Bailey SS, Pokorney A, Ayers SL, Valencia AM, Olson ML, Shaibi GQ. Organ fat in Latino youth at risk for type 2 diabetes. Pediatr Diabetes 2022;23:286-90. [PMID: 35001468 DOI: 10.1111/pedi.13311] [Reference Citation Analysis]
|
| 19 |
Harvey BE. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin 2022;43:1210-4. [PMID: 35110697 DOI: 10.1038/s41401-021-00832-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 20 |
Suwimol S, Pisit T, Anchalee A, Narisorn K, Jureeporn J, Wiroj J. Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand. PLoS One 2022;17:e0263826. [PMID: 35176047 DOI: 10.1371/journal.pone.0263826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Elabd EY, El-beik DEMS, Bayoumy EM, Saleh M, Ezzat WM, Siddik RI, Mohamed AE, Sayed MM, Ali MO. Diagnostic Value of Acyl-Ghrelin in Type 2 Diabetic Patients with Non-alcoholic Fatty Liver Disease. Open Access Maced J Med Sci 2022;10:470-476. [DOI: 10.3889/oamjms.2021.7548] [Reference Citation Analysis]
|
| 22 |
Hazem RM, Ibrahim AZ, Ali DA, Moustafa YM. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022;104:108503. [PMID: 34998036 DOI: 10.1016/j.intimp.2021.108503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 23 |
Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Gupta A, Anoop S, Ansari IA, Prakash S, Misra A. High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus. Clin Nutr ESPEN 2021;46:519-26. [PMID: 34857244 DOI: 10.1016/j.clnesp.2021.08.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 26 |
Tomah S, Hamdy O, Abuelmagd MM, Hassan AH, Alkhouri N, Al-Badri MR, Gardner H, Eldib AH, Eid EA. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol 2021;8:e000780. [PMID: 34610926 DOI: 10.1136/bmjgast-2021-000780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
kaur P, Randhawa GK, Kumar Salwan S. A RANDOMISED, PROSPECTIVE, PARALLELAND OPEN LABEL STUDY TO COMPARE EFFICACY AND SAFETY OF METFORMIN PLUS ROSUVASTATIN AND GLIMEPIRIDE PLUS ROSUVASTATIN IN PATIENTS OF COEXISTING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE 2 DIABETES MELLITUS (T2DM). ijsr 2021. [DOI: 10.36106/ijsr/3101504] [Reference Citation Analysis]
|
| 28 |
Sofias AM, De Lorenzi F, Peña Q, Azadkhah Shalmani A, Vucur M, Wang JW, Kiessling F, Shi Y, Consolino L, Storm G, Lammers T. Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Adv Drug Deliv Rev 2021;175:113831. [PMID: 34139255 DOI: 10.1016/j.addr.2021.113831] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 29 |
Alhinai A, Patel K, Fonseca VA, Sebastiani G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications 2021;35:107978. [PMID: 34183247 DOI: 10.1016/j.jdiacomp.2021.107978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Errafii K, Al-Akl NS, Khalifa O, Arredouani A. Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J Transl Med 2021;19:235. [PMID: 34078383 DOI: 10.1186/s12967-021-02885-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 31 |
Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 32 |
Kabisch S, Markova M, Hornemann S, Sucher S, Pivovarova-Ramich O, Machann J, Hierholzer J, Rohn S, Pfeiffer AFH. Liver fat scores do not reflect interventional changes in liver fat content induced by high-protein diets. Sci Rep 2021;11:8843. [PMID: 33893355 DOI: 10.1038/s41598-021-87360-2] [Reference Citation Analysis]
|
| 33 |
Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatol Commun 2021;5:559-72. [PMID: 33860115 DOI: 10.1002/hep4.1637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 34 |
Salt IP, Nunes JRC, Fullerton MD. Metformin again? Atheroprotection mediated by macrophage AMPK and ATF1. Cardiovasc Res 2021;117:1233-4. [PMID: 33681999 DOI: 10.1093/cvr/cvab065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 35 |
Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 36 |
Amanatidou AI, Dedoussis GV. Construction and analysis of protein-protein interaction network of non-alcoholic fatty liver disease. Comput Biol Med 2021;131:104243. [PMID: 33550014 DOI: 10.1016/j.compbiomed.2021.104243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 37 |
Gardner H, Hamdy O. Oral GLP1 Analog: Where Does the Tide Go? Clin Med Insights Endocrinol Diabetes 2020;13:1179551420984130. [PMID: 33447122 DOI: 10.1177/1179551420984130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Amanatidou AI, Dedoussis GV. Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease.. [DOI: 10.1101/2020.12.01.406215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
